Clinical Trials Directory

Trials / Unknown

UnknownNCT03652896

Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma

Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma: A Randomized Controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Huazhong University of Science and Technology · Academic / Other
Sex
All
Age
17 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Anatomical liver resection was widely accepted as first line curative therapy for hepatocellular carcinoma. However, number of retrospective clinical studies showed no priority of anatomical resection for hepatocellular, compared with non-anatomical resection. Surgical resection margin is a essential factor that may affect tumor prognosis. It is controversial whether adequate liver resection margin is associated with improved survival outcome in patients with hepatocellular. There was few prospective clinical trial to investigate whether anatomical liver resection is superior to non-anatomical resection or liver resection with adequate margin is superior to that with inadequate margin. This prospective clinical trial aims at fix these issues.

Detailed description

In the anatomical liver resection group, liver segmentectomy or lobectomy is performed to insure curative resection (R0 resection). The region of liver resected is based on the anatomy or portal vein and hepatic vein. The liver pedicle of the tumor located lobe is exposed and dissected, which is principle to perform anatomical liver resection. In the non-anatomical liver resection group, the liver parenchyma transection is around 0-2 cm from the tumor margin, according to tumor size and location.

Conditions

Interventions

TypeNameDescription
PROCEDUREanatomical liver resectionLiver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.

Timeline

Start date
2019-01-01
Primary completion
2021-12-30
Completion
2023-12-30
First posted
2018-08-29
Last updated
2018-08-29

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03652896. Inclusion in this directory is not an endorsement.